Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Otitis Media - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Otitis Media - Pipeline Review, H1 2015', provides an overview of the Otitis Media's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Otitis Media - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Otitis Media - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Otitis Media Overview 8 Therapeutics Development 9 Pipeline Products for Otitis Media - Overview 9 Pipeline Products for Otitis Media - Comparative Analysis 10 Otitis Media - Therapeutics under Development by Companies 11 Otitis Media - Therapeutics under Investigation by Universities/Institutes 13 Otitis Media - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Otitis Media - Products under Development by Companies 17 Otitis Media - Products under Investigation by Universities/Institutes 18 Otitis Media - Companies Involved in Therapeutics Development 19 Arbor Pharmaceuticals, LLC. 19 BCO Pharma Ltd 20 Cellceutix Corporation 21 ContraFect Corporation 22 Cubist Pharmaceuticals, Inc. 23 GlaxoSmithKline plc 24 Laboratorios SALVAT S.A. 25 Otonomy, Inc. 26 Serum Institute of India Limited 27 Yuhan Corporation 28 Otitis Media - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 (fluocinolone acetonide + ciprofloxacin hydrochloride) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 AR-01 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 BCO-002 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 betahistine hydrochloride - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 brilacidin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 CF-309 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ciprofloxacin SR - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GSK-2189242A - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 P-13 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 SIILPCV-10 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 solithromycin - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 YH-1177 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Otitis Media - Recent Pipeline Updates 55 Otitis Media - Dormant Projects 72 Otitis Media - Product Development Milestones 73 Featured News & Press Releases 73 Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes 73 Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 74 May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery 74 Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections 75 Dec 11, 2013: Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76 Aug 20, 2013: Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76 May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes 77 Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections 78 Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201 79 Dec 30, 2010: 13therapeutics Completes Pre-IND Meeting With FDA 80 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 82 Disclaimer 82
List of Tables Number of Products under Development for Otitis Media, H1 2015 9 Number of Products under Development for Otitis Media - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Late Stage Development, H1 2015 14 Comparative Analysis by Clinical Stage Development, H1 2015 15 Comparative Analysis by Early Stage Development, H1 2015 16 Products under Development by Companies, H1 2015 17 Products under Investigation by Universities/Institutes, H1 2015 18 Otitis Media - Pipeline by Arbor Pharmaceuticals, LLC., H1 2015 19 Otitis Media - Pipeline by BCO Pharma Ltd, H1 2015 20 Otitis Media - Pipeline by Cellceutix Corporation, H1 2015 21 Otitis Media - Pipeline by ContraFect Corporation, H1 2015 22 Otitis Media - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 23 Otitis Media - Pipeline by GlaxoSmithKline plc, H1 2015 24 Otitis Media - Pipeline by Laboratorios SALVAT S.A., H1 2015 25 Otitis Media - Pipeline by Otonomy, Inc., H1 2015 26 Otitis Media - Pipeline by Serum Institute of India Limited, H1 2015 27 Otitis Media - Pipeline by Yuhan Corporation, H1 2015 28 Assessment by Monotherapy Products, H1 2015 29 Assessment by Combination Products, H1 2015 30 Number of Products by Stage and Target, H1 2015 32 Number of Products by Stage and Mechanism of Action, H1 2015 34 Number of Products by Stage and Route of Administration, H1 2015 36 Number of Products by Stage and Molecule Type, H1 2015 38 Otitis Media Therapeutics - Recent Pipeline Updates, H1 2015 55 Otitis Media - Dormant Projects, H1 2015 72
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
